Advertisement

Should we be afraid of moderate hyperkalemia in HFrEF outpatients?

Published:October 25, 2022DOI:https://doi.org/10.1016/j.ijcard.2022.10.148
      Potassium (K+) is essential for cellular homeostasis and its disturbances are frequent in heart failure (HF) patients, potentially leading to life-threatening conditions. Hyperkalemia has been reported in almost 20% of patients with reduced ejection fraction heart failure (HFrEF) and represents a concern for clinicians, who often opt for therapy down-titration or discontinuation in case of severe hyperkalemia. Current evidence on moderate hyperkalemia is controversial, with a few reports arguing its association with HF therapy discontinuation, especially the reduction of renin-angiotensin-aldosterone system inhibitors (RAASi) dosage, more than with adverse events.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Toto F.
        • Salvioni E.
        • Magrì D.
        • Sciomer S.
        • Piepoli M.
        • Badagliacca R.
        • et al.
        Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data base.
        Int. J. Cardiol. 2022;
        • Badr Eslam R.
        • Öztürk B.
        • Panzer S.
        • Qin H.
        • Duca F.
        • Binder C.
        • et al.
        Low serum potassium levels and diabetes - an unfavorable combination in patients with heart failure and preserved ejection fraction.
        Int. J. Cardiol. 2020; 317: 121-127
        • Kovesdy C.P.
        • Matsushita K.
        • Sang Y.
        • Brunskill N.J.
        • Carrero J.J.
        • Chodick G.
        • et al.
        Serum potassium and adverse outcomes across the range of kidney function: a CKD prognosis consortium meta-analysis.
        Eur. Heart J. 2018; 39: 1535-1542
        • Ekundayo O.J.
        • Adamopoulos C.
        • Ahmed M.I.
        • Pitt B.
        • Young J.B.
        • Fleg J.L.
        • et al.
        Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study.
        Int. J. Cardiol. 2010; 141: 167-174
        • Komajda M.
        • Anker S.D.
        • Cowie M.R.
        • Filippatos G.S.
        • Mengelle B.
        • Ponikowski P.
        • et al.
        Physicians’ adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey.
        Eur. J. Heart Fail. 2016; 18: 514-522
        • Rossignol P.
        • Lainscak M.
        • Crespo-Leiro M.G.
        • Laroche C.
        • Piepoli M.F.
        • Filippatos G.
        • et al.
        Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP heart failure long-term registry.
        Eur. J. Heart Fail. 2020; 22: 1378-1389
        • Li X.
        • Zuo C.
        • Chen C.
        • Tian D.
        • Li J.
        • Fan L.
        • et al.
        Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: a prospective cohort study.
        Int. J. Cardiol. 2022;
        • Desai A.S.
        • Vardeny O.
        • Claggett B.
        • McMurray J.J.
        • Packer M.
        • Swedberg K.
        • et al.
        Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of Sacubitril/valsartan compared with Enalapril.
        JAMA Cardiol. 2017; 2: 79
        • Butler J.
        • Anker S.D.
        • Lund L.H.
        • Coats A.J.S.
        • Filippatos G.
        • Siddiqi T.J.
        • et al.
        Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
        Eur. Heart J. 2022;

      Linked Article